Page last updated: 2024-12-11

cpp 199

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norzimelidine: pharmacologically active N-demethylated metabolite of zimelidine; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5378630
CHEMBL ID287064
SCHEMBL ID2111009
MeSH IDM0068442

Synonyms (31)

Synonym
nomelidine
(z)-3-[1-(p-bromophenyl)-3-(methylamino)propenyl]pyridine
nomelidina [inn-spanish]
(z)-3-(4-bromphenyl)-n-methyl-3-(3-pyridyl)allylamin
(z)-3-(1-(p-bromophenyl)-3-(methylamino)propenyl)pyridine
nomelidine [inn]
nomelidinum [inn-latin]
a 24356
norzimelidine
a-24356
cpp-199
CHEMBL287064 ,
bdbm50020707
cis -[3-(4-bromo-phenyl)-3-pyridin-3-yl-allyl]-methyl-amine ;c2h4o4
trans-[3-(4-bromo-phenyl)-3-pyridin-3-yl-allyl]-methyl-amine;c2h4o4
[3-(4-bromo-phenyl)-3-pyridin-3-yl-allyl]-methyl-amine(norzimeldine)
(z)-3-(4-bromophenyl)-n-methyl-3-pyridin-3-ylprop-2-en-1-amine
fvl27c1dmg ,
nomelidina
unii-fvl27c1dmg
nomelidinum
60324-59-6
SCHEMBL2111009
(2z)-3-(4-bromophenyl)-n-methyl-3-(3-pyridinyl)-2-propen-1-amine #
AZFZKANGXPSDEA-NVNXTCNLSA-N
(z)-3-(bromophenyl)-n-methyl-3-(3-pyridyl)-allylamine
(z)-norzimelidine
2-propen-1-amine, 3-(4-bromophenyl)-n-methyl-3-(3-pyridinyl)-, (z)-
Q27278232
DTXSID501024244
AKOS040749036

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The possible influence of concomitant food intake on the bioavailability of the novel antidepressant zimeldine and its active metabolite norzimeldine was assessed in ten healthy female volunteers, who ingested a single dose of 200 mg zimeldine on an empty stomach and together with a standardized breakfast of 1 840 kJ."( Influence of food intake on the bioavailability of zimeldine and its active metabolite, norzimeldine.
Melander, A; Wahlén, A; Wåhlin-Boll, E; Westerlund, D, 1983
)
0.27
" It appears that zimelidine is completely absorbed from the gastrointestinal tract and "first-pass metabolism" in the liver reduces the bioavailability to 50%."( Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine.
Chaturvedi, S; Love, BL; Moore, RG; Thomas, J, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
" The results suggest that zimeldine can be administered in a once daily dosage regimen to elderly patients, but they should be given a lower dose than younger patients."( Zimeldine to geriatric patients in once daily dosage. A pharmacokinetic and clinical study.
Björnson, G; Dehlin, O; Lundström, J; Nörgård, J, 1984
)
0.27
"The acute interaction of zimelidine (Z) with ethanol (E) was examined in six healthy men aged 20 to 37 yr who randomly received each of four treatments 1 wk apart: Z, 200 mg by mouth, preceded by 1 hr and followed for 7 hr of oral E in juice dosed to maintain blood alcohol concentrations between 800 and 1000 mg/l; placebo Z and E; Z and juice; and placebo Z and juice."( Acute kinetic and dynamic interactions of zimelidine with ethanol.
Hamilton, C; Kaplan, HL; Khouw, V; Naranjo, CA; Sellers, EM, 1984
)
0.27
" With the applied, probably suboptimal, dosage the therapeutic response was only satisfactory in five cases."( Plasma levels of zimelidine and norzimelidine in endogenous depression.
Hansen, LB; Hvidberg, EF; Larsen, NE; Thomsen, IS; Vestergård, P, 1980
)
0.26
" Blood and urine samples were collected for a period of 28 hours after dosing and the concentrations of zimelidine and norzimelidine determined."( Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine.
Chaturvedi, S; Love, BL; Moore, RG; Thomas, J, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID132433Ex vivo inhibition of the accumulation of (-)-[3H]Norepinephrine in slices from the middle part of the mouse brain. (i.p.)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID130699In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID132666In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID232041Selectivity expressed as ratio between NE and 5-HT uptake inhibition in mouse brain slices1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID130700In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID179753In vitro inhibition of the accumulation of (-)-[3H]Norepinephrine in synaptosomes from the rat brain cortex1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID132671In vitro inhibition of the accumulation of (-)-[3H]-5-HT in slices from the middle part of the mouse brain.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID179752In vitro inhibition of the accumulation of (-)-[3H]-5-HT in synaptosomes from the rat brain cortex1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID132665In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID232042Selectivity expressed as ratio between NE and 5-HT uptake inhibition in rat synaptosomes1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID132672In vitro inhibition of the accumulation of (-)-[3H]Norepinephrine in slices from the middle part of the mouse brain.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID132432Ex vivo inhibition of the accumulation of (-)-[3H]-5-HT in slices from the middle part of the mouse brain. (i.p.)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (94.74)18.7374
1990's2 (5.26)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.37 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (14.29%)5.53%
Reviews1 (2.38%)6.00%
Case Studies5 (11.90%)4.05%
Observational0 (0.00%)0.25%
Other30 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]